تقرير
A Case of Success: Complete Response to Radium-223 in Metastatic Castration-Resistant Prostate Cancer.
| العنوان: | A Case of Success: Complete Response to Radium-223 in Metastatic Castration-Resistant Prostate Cancer. |
|---|---|
| المؤلفون: | Soares de Pinho I; Medical Oncology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (North Lisbon University Hospital Center), Lisbon, PRT., Esperança-Martins M; Medical Oncology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (North Lisbon University Hospital Center), Lisbon, PRT.; Oncology, Luis Costa Lab, Instituto de Medicina Molecular (Institute of Molecular Medicine), Lisbon, PRT., Machado B; Medical Oncology, Centro Hospitalar Entre Douro e Vouga (Hospital Center Entre Douro e Vouga), Santa Maria da Feira, PRT., Dâmaso S; Medical Oncology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (North Lisbon University Hospital Center), Lisbon, PRT., Lopes Brás R; Medical Oncology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (North Lisbon University Hospital Center), Lisbon, PRT., Cantinho G; Nuclear Medicine, Faculdade de Medicina, Universidade de Lisboa (Faculty of Medicine, University of Lisbon), Lisbon, PRT., Fernandes I; Oncology, Hospital CUF Descobertas, Lisbon, PRT.; Research, Comprehensive Health Research Center, Nova Medical School, Lisbon, PRT.; Research, EpiDoC, Nova Medical School, Lisbon, PRT., Costa L; Medical Oncology, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte (North Lisbon University Hospital Center), Lisbon, PRT.; Oncology, Luis Costa Lab, Instituto de Medicina Molecular (Institute of Molecular Medicine), Lisbon, PRT. |
| المصدر: | Cureus [Cureus] 2024 Feb 05; Vol. 16 (2), pp. e53637. Date of Electronic Publication: 2024 Feb 05 (Print Publication: 2024). |
| نوع المنشور: | Case Reports |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cureus, Inc Country of Publication: United States NLM ID: 101596737 Publication Model: eCollection Cited Medium: Print ISSN: 2168-8184 (Print) Linking ISSN: 21688184 NLM ISO Abbreviation: Cureus Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Palo Alto, CA : Cureus, Inc. |
| مستخلص: | Radium-223 dichloride (Ra223) is the first targeted alpha agent approved for treating metastatic castration-resistant prostate cancer (mCRPC) with bone-exclusive disease. A benefit in overall survival and time to the first symptomatic skeletal-related event was shown in the Alpharadin in Symptomatic Prostate Cancer Patients (ALSYMPCA) trial. However, this trial did not describe a bone scan response to Ra223, and there is no universal consensus about how it should be monitored. Furthermore, a scintigraphy flare phenomenon may lead to false-positive tracer uptake in responsive cases, thereby misleading the interpretation of imaging results. We present the case of a 67-year-old male with mCRPC and exclusive bone disease treated with Ra223. The bone scintigraphy after the end of the treatment showed an apparent aggravation of the lesions, corresponding to a flare phenomenon, with an almost complete resolution after three months. The patient maintained a scintigraphic response for seven months. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2024, Soares de Pinho et al.) |
| References: | N Engl J Med. 2013 Jul 18;369(3):213-23. (PMID: 23863050) Lancet Oncol. 2019 Mar;20(3):408-419. (PMID: 30738780) Clin Genitourin Cancer. 2018 Oct;16(5):349-354. (PMID: 29778323) Support Care Cancer. 2007 Jul;15(7):869-76. (PMID: 17262196) Lancet Oncol. 2002 Aug;3(8):453. (PMID: 12147423) Radiology. 2014 Apr;271(1):220-9. (PMID: 24475817) Support Care Cancer. 2015 Jan;23(1):237-47. (PMID: 25270847) Cancer Res. 2002 Jun 1;62(11):3120-5. (PMID: 12036923) Lancet Oncol. 2005 Jun;6(6):392-400. (PMID: 15925817) Front Endocrinol (Lausanne). 2022 Dec 16;13:1063815. (PMID: 36589815) J Natl Cancer Inst. 2002 Oct 2;94(19):1458-68. (PMID: 12359855) Oncol Lett. 2019 Feb;17(2):1467-1476. (PMID: 30675201) Clin Cancer Res. 2006 Oct 15;12(20 Pt 2):6250s-6257s. (PMID: 17062709) Lancet. 2012 Jan 7;379(9810):39-46. (PMID: 22093187) J Clin Oncol. 2016 Apr 20;34(12):1402-18. (PMID: 26903579) Asia Pac J Clin Oncol. 2018 Nov;14 Suppl 5:16-23. (PMID: 30489033) Ther Adv Med Oncol. 2021 Feb 24;13:1758835920987654. (PMID: 33708265) |
| فهرسة مساهمة: | Keywords: bone disease; flare; prostate cancer; radium-223; response |
| تواريخ الأحداث: | Date Created: 20240307 Latest Revision: 20240308 |
| رمز التحديث: | 20240308 |
| مُعرف محوري في PubMed: | PMC10917398 |
| DOI: | 10.7759/cureus.53637 |
| PMID: | 38449973 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2168-8184 |
|---|---|
| DOI: | 10.7759/cureus.53637 |